genes

an Open Access Journal by MDPI

IMPACT FACTOR 2.8

Indexed in: PubMed

CITESCORE 5.2

# Study of Inherited Retinal Diseases

Guest Editor:

**Prof. Dr. Se Joon Woo**
Professor of Department of Ophthalmology, Seoul National University Bundang Hospital, 173-82 Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13620, Republic of Korea

Deadline for manuscript submissions:
**closed (10 June 2022)**

## Message from the Guest Editor

Inherited retinal disease (IRD) is a major cause of bilateral visual decline and blindness worldwide. To date, there is no definitive treatment option for this condition. Recently, there have been advances in the field of genetic diagnosis and treatment methods, including gene therapy and genome editing. Since the approval of gene therapy for RPE65-related IRD, the future of treatment of IRD appears bright, and more patients with IRD may be saved from blindness as technology develops. To reach a better visual outcome for IRD patients, a greater understanding of IRD, including genetics, mechanism, clinical features, and preclinical and clinical trial results are needed for physicians, researchers, and patients, as well as pharmaceutical companies and governments.

In this Special Issue, we welcome reviews and original articles about the study of IRD. These include, but are not limited to, genetics and molecular mechanisms of IRD, diagnosis, clinical features and imaging of IRD cases, epidemiology, ethnic variability, preclinical research, and clinical trials of new treatments. We look forward to your contributions. Thank you.

GCAT TACG GCAT genes

IMPACT FACTOR 2.8 | Indexed in: PubMed | CITESCORE 5.2

an Open Access Journal by MDPI

## Editor-in-Chief

**Prof. Dr. Selvarangan Ponnazhagan**
Department of Pathology, The University of Alabama at Birmingham, 1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

## Message from the Editor-in-Chief

Genes are central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fastmoving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised.

Why not consider *Genes* for your next genetics paper?

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.
**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.
**Journal Rank:** JCR - Q2 (*Genetics and Heredity*) / CiteScore - Q2 (*Genetics (clinical)*)

## Contact Us

*Genes* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/genes
genes@mdpi.com
𝕏@Genes_MDPI